title: Development of an effective polyvalent vaccine against both Marek's and Newcastle diseases based on recombinant Marek's disease virus type 1 in commercial chickens with maternal antibodies.
abstract: An earlier report (M. Sakaguchi et al., Vaccine 16:472-479, 1998) showed that recombinant Marek's disease virus type 1 (rMDV1) expressing the fusion (F) protein of Newcastle disease virus (NDV-F) under the control of the simian virus 40 late promoter [rMDV1-US10L(F)] protected specific pathogen-free chickens from NDV challenge, but not commercial chickens with maternal antibodies against NDV and MDV1. In the present study, we constructed an improved polyvalent vaccine based on MDV1 against MDV and NDV in commercial chickens with maternal antibodies. The study can be summarized as follows. (i) We constructed rMDV1 expressing NDV-F under the control of the MDV1 glycoprotein B (gB) promoter [rMDV1-US10P(F)]. (ii) Much less NDV-F protein was expressed in cells infected with rMDV1-US10P(F) than in those infected with rMDV1-US10L(F). (iii) The antibody response against NDV-F and MDV1 antigens of commercial chickens vaccinated with rMDV1-US10P(F) was much stronger and faster than with rMDV1-US10L(F), and a high level of antibody against NDV-F persisted for over 80 weeks postvaccination. (iv) rMDV1-US10P(F) was readily reisolated from the vaccinated chickens, and the recovered viruses were found to express NDV-F. (v) Vaccination of commercial chickens having maternal antibodies to rMDV1-US10P(F) completely protected them from NDV challenge. (vi) rMDV1-US10P(F) offered the same degree of protection against very virulent MDV1 as the parental MDV1 and commercial vaccines. These results indicate that rMDV1-US10P(F) is an effective and stable polyvalent vaccine against both Marek's and Newcastle diseases even in the presence of maternal antibodies.
authors.affiliation: The Chemo-Sero Therapeutic Research Institute, Kikuchi Research Center, Kyokushi Kikuchi, Kumamoto 869-1298, Japan.
authors.forename: K
authors.initials: K
authors.lastname: Sonoda
authors.forename: M
authors.initials: M
authors.lastname: Sakaguchi
authors.forename: H
authors.initials: H
authors.lastname: Okamura
authors.forename: K
authors.initials: K
authors.lastname: Yokogawa
authors.forename: E
authors.initials: E
authors.lastname: Tokunaga
authors.forename: S
authors.initials: S
authors.lastname: Tokiyoshi
authors.forename: Y
authors.initials: Y
authors.lastname: Kawaguchi
authors.forename: K
authors.initials: K
authors.lastname: Hirai
mesh_terms: D000818:Animals; D000914:Antibodies, Viral / Q000276:immunology*; D001483:Base Sequence; D002645:Chickens; D008381:Herpesvirus 2, Gallid / Q000235:genetics / Q000276:immunology*; D008380:Marek Disease / Q000517:prevention & control*; D008969:Molecular Sequence Data; D009521:Newcastle Disease / Q000517:prevention & control*; D009522:Newcastle disease virus / Q000302:isolation & purification; D012333:RNA, Messenger / Q000235:genetics; D011995:Recombination, Genetic; D013539:Simian virus 40 / Q000235:genetics; D014132:Trachea / Q000821:virology; D014764:Viral Proteins / Q000235:genetics; D014765:Viral Vaccines / Q000235:genetics* / Q000276:immunology
chemical_list: D000914:Antibodies, Viral; D012333:RNA, Messenger; D014764:Viral Proteins; D014765:Viral Vaccines